PPV without ILM peeling favourable for ODP

Article

Pars plana vitrectomy, endolaser photocoagulation and C3F8 gas tamponade without internal limiting membrane (ILM) peeling have been found to be potentially favourable in the treatment of optic disc pit (ODP) maculopathy, according to data published in Eye.

Pars plana vitrectomy, endolaser photocoagulation and C3F8 gas tamponade without internal limiting membrane (ILM) peeling have been found to be potentially favourable in the treatment of optic disc pit (ODP) maculopathy, according to data published in Eye.

Dr R. Avci et al. (Retina Eye Hospital, Bursa, Turkey) examined 13 eyes from 12 patients undergoing surgery to treat serous macular detatchment and/or macular retinoschisis secondary to congenital ODP. All patients included in the study were treated with PPV, posterior hyaloid removal, endolaser photocoagulation on the temporal margin of the optic disc and 12% C3F8 gas tamponade.

The team used optical coherence tomography (OCT) to analyse the anatomic success and functional outcome of surgery and they measured the patients’ best-corrected visual acuity (BCVA) as well. The majority of the study group experienced an improvement in BCVA of 2 lines or more and 12 eyes experienced complete reabsorption or subretinal and intraretinal fluid.

These results indicated that PPV, C3F8 gas tamponade and endolaser to the optic disc margin without ILM peeling could be a beneficial surgical option for patients suffering with ODP maculopathy and earlier surgical intervention leads to better visual improvements.

For further information please view the abstract here.

Related Videos
Ana Neves, head of global marketing for ZEISS Meditec Ophthalmology
Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany
Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London
Kasperi Kankare at the iCare booth at ESCRS
Scott D Barnes, MD, CMO of STAAR Surgical
Tomislav Bucalic, head of marketing at Geuder, and David Geuder, member of the executive board and CIO
Related Content
© 2023 MJH Life Sciences

All rights reserved.